Long-acting bronchodilators in combination with inhaled corticosteroids (ICS) are
recommended to decrease the risk of recurrent exacerbations in patients with Global …

Recent reports provide evidence-based guidelines for the withdrawal of inhaled
corticosteroids (ICS) in COPD, but data on patients treated with ICS-based triple therapy are …

Background It has been suggested that withdrawal of inhaled corticosteroids (ICS) in COPD
patients on maintenance treatment results in deterioration of symptoms, lung function and …

Introduction To date, there is solid evidence from randomized controlled trials (RCTs)
supporting the rationale for withdrawal from inhaled corticosteroids (ICSs) in most patients …

Current guidelines for the management of chronic obstructive pulmonary disease (COPD)
recommend limiting the use of inhaled corticosteroids (ICS) to patients with more severe …

Clinical trials in chronic obstructive pulmonary disease (COPD) patients have shown that the
long-term use of inhaled corticosteroids (ICS) in COPD patients reduced the number of …

Background Treatment with inhaled glucocorticoids in combination with long-acting
bronchodilators is recommended in patients with frequent exacerbations of severe chronic …

The use of inhaled corticosteroids (ICS) in the treatment of chronic obstructive pulmonary
disease (COPD) has been widely debated [1–3]. Treatment guidelines have suggested that …

The combination of an inhaled long-acting β2-agonist with an inhaled corticosteroid (ICS) is
widely used in the management of chronic obstructive pulmonary disease (COPD), primarily …

Background: Several clinical trials have evaluated the benefits associated with adding an
inhaled corticosteroid (ICS) to a long-acting bronchodilator in the treatment of severe or very …